上海交通大学学报(医学版) ›› 2019, Vol. 39 ›› Issue (8): 919-.doi: 10.3969/j.issn.1674-8115.2019.08.019

• 综述 • 上一篇    下一篇

强迫症增效治疗机制的研究进展

任延燕,王振   

  1. 上海交通大学医学院附属精神卫生中心,上海 200030
  • 出版日期:2019-08-28 发布日期:2019-09-23
  • 通讯作者: 王振,电子信箱:wangzhen@smhc.org.cn。
  • 作者简介:任延燕(1992—),女,硕士生;电子信箱: 15921992935@163.com。
  • 基金资助:
    国家自然科学基金(81671340);上海市教育委员会高峰高原学科建设计划(20161321)

Progress in augmentation therapy mechanism of obsessive compulsive disorder

REN Yan-yan, WANG Zhen   

  1. Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China
  • Online:2019-08-28 Published:2019-09-23
  • Supported by:
    National Natural Science Foundation of China, 81671340; Shanghai Municipal Education Commission—Gaofeng Clinical Medicine Support, 20161321

摘要: 目前,治疗强迫症最常用的药物是选择性 5-羟色胺再摄取抑制剂,但约半数患者服药无效,临床治疗时通常加用抗精神病药作为增效剂。增效剂可使部分患者症状好转,但对部分患者仍无增效作用。因此,研究增效剂起效的机制,根据相关机制改进治疗措施,对指导临床治疗具有重要意义。该文主要对强迫症增效治疗的机制进行综述。

关键词: 强迫症, 增效剂, 选择性 5-羟色胺再摄取抑制剂, 抗精神病药

Abstract:

Administration of selective serotonin reuptake inhibitors (SSRI) is a widely used pharmacotherapeutic approach for obsessive-compulsive disorder (OCD) today. However, nearly half of the OCD patients do not respond to SSRI. It has been shown that some antipsychotic drugs can augment the therapeutic effect of SSRI in the patients with OCD, but the augmentation’s effect is still ineffective for some patients.Therefore, it is of great significance to explore the augmentation’s mechanism for further improvement of the clinical treatment. This article reviews some common used augmentation for OCD and discusses the underlying mechanisms.

Key words: obsessive compulsive disorder (OCD), augmentation, selective serotonin reuptake inhibitor (SSRI), antipsychotics

中图分类号: